Mabion SA | Mabion cGMP Facility

At Mabion, we believe the future of biosimilar development will be shaped by smart partnerships, shared vision, innovative collaboration models, and strong biologics development and manufacturing capabilities.We are looking to meet companies interested in co-creating high-value biosimilar programs through flexible, partner-centric structures that go beyond traditional development models. These may include early-licensing opportunities, co-development, risk-sharing, asset-focused partnerships, and broader strategic alliances. By combining complementary capabilities, scientific expertise, strategic alignment from the earliest stages, and integrated large molecule development and manufacturing know-how, we aim to accelerate development, reduce complexity, and unlock greater value for patients, partners, and healthcare systems.Our partnership approach is built around collaborative value creation. Mabion aims to act as a biologics development and manufacturing partner, bringing together technical execution, process development, analytical expertise, regulatory understanding, and strategic collaboration to support shared product and business objectives.At BIO International, we invite you to connect with us to explore joint biosimilar development opportunities, including early-licensing, co-development, risk-sharing, asset-focused partnerships, and broader strategic alliances designed around mutual success. We are particularly interested in discussions with companies seeking a partner for biosimilar development, large molecule manufacturing, and innovation-oriented biologics programs where collaboration can begin early and evolve around mutual value creation.We are also open to exploring partnerships around next-generation ADC linker technologies, particularly solutions designed to enhance stability, improve payload delivery, support manufacturability, and enable differentiated ADC product concepts.Where relevant, we welcome discussions on CD20-targeting approaches in rare and orphan diseases, especially where B-cell modulation could open new therapeutic opportunities beyond established indications. This includes innovation-driven concepts where Mabion’s biologics expertise, development capabilities, and large molecule manufacturing know-how may support differentiated therapeutic approaches.Mabion is a public company listed on the Warsaw Stock Exchange (WSE: MAB). For more information about the Company, please visit www.mabion.eu.